Sign inJoin waitlistJoin the waitlist

Daniel Geynisman

Chief, Division of Genitourinary Medical Oncology · Temple University Hospital

Credentials: · · ·

History

Division of Genitourinary Medical Oncology · Temple University Hospital
Present
Quality Improvement Program · Temple University Hospital
Present
Temple University Hospital
Present

University of Chicago
2009–2011
Internal Medicine
2006–2009
University of Pittsburgh School of Medicine
2002–2006

Research

Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
The Lancet Oncology · 2021 · 369 citations
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network · 2019 · 244 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
Journal of Clinical Oncology · 2023 · 187 citations

Elizabeth Plimack
56 papers
Matthew Zibelman
38 papers · 1 as a fellow
Alexander Kutikov
31 papers
Robert Uzzo
31 papers
Pooja Ghatalia
28 papers · 8 as a fellow
Marc Smaldone
23 papers · 13 as a resident
David Chen
18 papers
RG
Richard Greenberg
17 papers
Rosalia Viterbo
14 papers
Fern Anari
13 papers · 2 as a fellow
Eric Horwitz
11 papers
YW
Yu-Ning Wong
11 papers

Clinical trials

Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Principal investigator · Recruiting · Phase 2
Fox Chase Cancer Center
2025–2031
Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients
Principal investigator · Completed · Phase 2
Fox Chase Cancer Center
2015–2020
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
Site PI · Recruiting · Phase 1
Deciphera Pharmaceuticals, LLC
2025–2029
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
Sub-investigator · Unknown · Phase 1, Phase 2
Eutilex
2021–2025